Plandai Biotechnology, Inc. Product Proven to Decrease Healing Time of Sports-Related Injuries

NEW YORK, NY--(Marketwired - May 21, 2013) -  In a series of articles to introduce Plandaí Biotechnology, Inc.'s (OTCQB: PLPL) three highly bioavailable products, the second of three introduces what could be the go-to solution for the common cold. All of Plandaí's extracts will be individually labeled and marketed under the Phytofare™ brand.

Much like its first product, Phytofare™ Catechin Extract, Plandaí's Phytofare™ Limonoid Glycoside Complex will hit the market and offer the company's customers a higher absorption rate than the market's current products can deliver. The citrus derived Limonoid Glycoside Complex is a unique product that utilizes the entire lemon fruit including juice, pith, peel, and pulp from where all the soluble phytonutrients are recovered.

It is an extract that is formulated to contain any or all of vitamins A & C, bioflavonoids, (Hesperidin and Rutin), limonoids (limonin and nomilin), and numerous minerals, including potassium and pectin. The resulting complex has been scientifically proven to improve and maintain capillary integrity; fight infections, relieve the common cold and flu symptoms; reduce inflammation, and decrease the healing time of sports-related injuries.

In the early 1960's, the US Olympic Team used Citrus Bioflavonoids for track and field athletes. They found that muscle pulls were virtually eliminated and injuries healed twice as fast. With the improved healing times from using a Citrus Complex, athletes can train longer and harder, yielding improved performance results.

While research into commercializing a citrus complex containing limonoids has stalled in the past, Plandaí intends to be the first to enter this market with a high-purity and water-soluble citrus complex once supporting human clinical trials are completed.

Just as with the company's first product, Phytofare™ Catechin Extract, Plandaí will use its proprietary hydrodynamic sheering process where live plant-materials are converted at the molecular level during extraction into a nano-particle sized isomeric structure that resembles that found in human tissues.

Continue reading this Article at www.stockhousegroup.com/features.

About Stock House Group
Stock House Group is a full service Investment Relations firm specializing in Research, Content Development and Awareness. The firm offers a platform for CEOs to tell their story through the press with Feature Articles, Research Reports, and CEO Interviews. At the same time, the company is building a library of Research for Investors to become better informed on small cap stocks. For more information: www.stockhousegroup.com.